Business in Brief
The latest business news in the world of diagnostic medicine
Luke Turner | | Quick Read
Making a Mark
A PCR-based test for determining microsatellite instability (MSI) status in solid tumors has received the CE mark as a new in vitro diagnostic medical device. OncoMate™ MSI provides a DNA-based MSI reading complementary to a standard MMR immunohistochemistry panel, which can be used to predict response to immuno-oncology therapies (1).
Read the full article now
Log in or register to read this article in full and gain access to The Pathologist’s entire content archive. It’s FREE!
Or register now - it’s free!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Pathologist magazine